Login to Your Account

Cash trek: Voyager seeks up to $86.3M to fund quest for CNS therapies

By Michael Fitzhugh
Staff Writer

Monday, October 12, 2015
Voyager Therapeutics Inc., a gene therapy company advancing adeno-associated virus (AAV) treatments for five central nervous system (CNS) disorders, has filed to raise up to $86.3 million in a yet-to-price IPO.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription